{"version":"1.0","type":"link","title":"HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).","author_name":"Wu HL 외","author_url":"https://prs-insight.online/author/Wu%20HL","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/76576","thumbnail_width":1200,"thumbnail_height":630}